236 related articles for article (PubMed ID: 36672738)
1. Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo.
Fetisov TI; Borunova AA; Antipova AS; Antoshina EE; Trukhanova LS; Gorkova TG; Zuevskaya SN; Maslov A; Gurova K; Gudkov A; Lesovaya EA; Belitsky GA; Yakubovskaya MG; Kirsanov KI
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672738
[TBL] [Abstract][Full Text] [Related]
2. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
3. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K
Front Oncol; 2022; 12():863329. PubMed ID: 35677155
[TBL] [Abstract][Full Text] [Related]
4. Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms.
Jin MZ; Xia BR; Xu Y; Jin WL
Front Oncol; 2018; 8():598. PubMed ID: 30581774
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Colorectal Carcinogenesis by DNA-Binding Small-Molecule Curaxin CBL0137 Involves Suppression of Wnt Signaling.
Kirsanov K; Fetisov T; Lesovaya EA; Maksimova V; Trukhanova L; Antoshina E; Gor'kova T; Morozova O; Safina A; Fleyshman D; Salimov R; Shipaeva E; Ivanov R; Leonov A; Purmal AA; Belitsky GA; Gudkov AV; Gurova KV; Yakubovskaya MG
Cancer Prev Res (Phila); 2020 Jan; 13(1):53-64. PubMed ID: 31653646
[TBL] [Abstract][Full Text] [Related]
6.
Forgione MO; McClure BJ; Page EC; Yeung DT; Eadie LN; White DL
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35323988
[TBL] [Abstract][Full Text] [Related]
7. Insights into the Mechanism of Curaxin CBL0137 Epigenetic Activity: The Induction of DNA Demethylation and the Suppression of BET Family Proteins.
Maksimova V; Popova V; Prus A; Lylova E; Usalka O; Sagitova G; Zhidkova E; Makus J; Trapeznikova E; Belitsky G; Yakubovskaya M; Kirsanov K
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629054
[TBL] [Abstract][Full Text] [Related]
8. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
9. Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy.
Singh A; Pruett N; Dixit S; Gara SK; Wang H; Pahwa R; Schrump DS; Hoang CD
J Exp Clin Cancer Res; 2023 Nov; 42(1):304. PubMed ID: 37974213
[TBL] [Abstract][Full Text] [Related]
10. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O'Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M
Clin Cancer Res; 2021 Aug; 27(15):4338-4352. PubMed ID: 33994371
[TBL] [Abstract][Full Text] [Related]
12. Novel anticancer drug curaxin CBL0137 impairs DNA methylation by eukaryotic DNA methyltransferase Dnmt3a.
Sergeev A; Vorobyov A; Yakubovskaya M; Kirsanova O; Gromova E
Bioorg Med Chem Lett; 2020 Aug; 30(16):127296. PubMed ID: 32631516
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy.
Chen M; Brackett CM; Burdelya LG; Punnanitinont A; Patnaik SK; Matsuzaki J; Odunsi AO; Gudkov AV; Singh AK; Repasky EA; Gurova KV
Cancer Immunol Immunother; 2021 Jul; 70(7):2073-2086. PubMed ID: 33439292
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers.
Dallavalle S; Mattio LM; Artali R; Musso L; Aviñó A; Fàbrega C; Eritja R; Gargallo R; Mazzini S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204214
[TBL] [Abstract][Full Text] [Related]
15. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27650817
[TBL] [Abstract][Full Text] [Related]
16. Curaxin-Induced DNA Topology Alterations Trigger the Distinct Binding Response of CTCF and FACT at the Single-Molecule Level.
Lu K; Liu C; Liu Y; Luo A; Chen J; Lei Z; Kong J; Xiao X; Zhang S; Wang YZ; Ma L; Dou SX; Wang PY; Li M; Li G; Li W; Chen P
Biochemistry; 2021 Feb; 60(7):494-499. PubMed ID: 33570402
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory cell death PANoptosis is induced by the anti-cancer curaxin CBL0137 via eliciting the assembly of ZBP1-associated PANoptosome.
Li YP; Zhou ZY; Yan L; You YP; Ke HY; Yuan T; Yang HY; Xu R; Xu LH; Ouyang DY; Zha QB; He XH
Inflamm Res; 2024 Apr; 73(4):597-617. PubMed ID: 38353723
[TBL] [Abstract][Full Text] [Related]
18. Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis.
Ding H; Jiang M; Lau CW; Luo J; Chan AM; Wang L; Huang Y
Br J Pharmacol; 2023 Apr; 180(8):1168-1185. PubMed ID: 36495259
[TBL] [Abstract][Full Text] [Related]
19. CBL0137 administration suppresses human hepatocellular carcinoma cells proliferation and induces apoptosis associated with multiple cell death related proteins.
Albahde MAH; Zhang P; Chen H; Wang W
Neoplasma; 2020 May; 67(3):547-556. PubMed ID: 32202904
[TBL] [Abstract][Full Text] [Related]
20. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
